Проблеми екології та медицини, Том 24, № 5-6

Постійне посилання зібрання

https://repository.pdmu.edu.ua/handle/123456789/15612

Переглянути

Перегляд Проблеми екології та медицини, Том 24, № 5-6 за Автор "Kaidashev, I. P."

Зараз показуємо 1 - 1 з 1
  • Ескіз недоступний
    Документ
    Application of pioglitazone in the comprehensive treatment of psoriatic patients with concomitant alimentary obesity
    (Полтавський державний медичний університет, 2020) Yemchenko, Ya. O.; Ishcheikin, K. Ye.; Kaidashev, I. P.; Ємченко, Яна Олександрівна; Іщейкін, Костянтин Євгенович; Кайдашев, Ігор Петрович
    Psoriasis is one of the most common chronic recurrent systemic autoimmune multifactorial diseases, in which the skin, joints, internal organs and systems of the body are involved in the pathological process. Despite the significant preva-lence of psoriasis and a large number of studies on this problem, there is still no single view on the pathogenesis of this dermatosis. To objectively understand the pathogenesis of psoriasis, it is necessary to take into account the insufficiently studied comorbidity of this pathology. Recently, an indisputable link between psoriasis and obesity has been proven. The scientific literature widely covers the issue of identical pathogenetic mechanisms of inflammatory processes in psoriasis and obesity. Given the current data on the role of systemic inflammation underlying the development of both psoriasis and obesity, the study of molecular mechanisms of its development and taking into account the role of proinflammatory nuclear transcription factors, thiazolidinediones are the pathogenetically justified drugs of choice for treatment of these diseases. In this study, we determined the effectiveness of using 15 mg of pioglitazone once a day for 6 months in the treatment of patients with extensive psoriasis vulgaris of moderate severity and concomitant grade І-ІІ alimentary obesity by clinical and immunological examination of systemic inflammation. Analyzing the results of the study, it was found that long-term use of pioglitazone, even in small doses, led to a decrease in systemic inflammation and con-tributed to a milder course of psoriasis in recurrence of the disease.